NCCN Request for Proposals (RFP): Combination Therapy with Relugolix in the Treatment of Advanced Prostate Cancer

Funding Agency:
National Comprehensive Cancer Network

The National Comprehensive Cancer Network®, Pfizer Global Medical Grants (Pfizer) and Myovant Sciences (Myovant) are collaborating to offer a new grant opportunity seeking proposals for investigator-initiated research with relugolix. Pfizer and Myovant Sciences (hereafter, “Grantor”) is providing $5 million in funding to support clinical research studies to further evaluate the effectiveness of relugolix in combination with other therapies for the treatment of advanced prostate cancer. The Grantor will serve as the funding organization. Grants are available to all investigators from institutions within the United States.   

Relugolix is a nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to pituitary GnRH receptors, thereby reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone. Relugolix is currently indicated for the treatment of adult patients with advanced prostate cancer, the only currently approved oral androgen deprivation therapy (ADT) for this indication. 

The overall aim is to d evelop innovative studies to advance scientific knowledge regarding combination therapies with relugolix in the treatment of patients with advanced prostate cancer, including high-risk or locally advanced primary, recurrent, or metastatic, in any state (androgen-sensitive or castrationresistant) . It is hoped that proposals submitted in response to this RFP will be useful to guide further development of relugolix. Studies with correlative endpoints are encouraged. 

Proposal submission deadline: May 22, 2023

Agency Website

Eligibility Requirements

• US institutions only. • Academic health care centers. • Community health care centers. • Health care professional organizations and other organizations related to health care improvement. • Health care delivery organizations must serve as the lead applicant, if partnered with health technology companies.

• Collaboration among institutions is strongly encouraged to foster interactive sharing of knowledge and expertise, and to utilize the combined strengths of the involved institutions. • Junior faculty (i.e., Assistant Professors and below) are encouraged to apply. • Trainees may participate as a sub-investigator under appropriate mentorship from a PI

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

May 22, 2023